Pas de connexion internet — affichage de la version enregistrée de la page.

Heron Therapeuti

USUSD
← Vers le screener
US:HRTXLSE:0J4V

Heron Therapeuti (US:HRTX) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
herontx.com
Relations avec les investisseurs
ir.herontx.com/
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
SAN DIEGO, United States
PDG
Craig Alexander Collard
Employés
128
Actions en circulation
189.85 M au 2026-08-05
Flottant
146.52 M
Capitalisation boursière
77.1 M USD
Initiés
0.98%
Investisseurs institutionnels
70.98%
Secteur d'activité (SIC)
Pharmaceutical Preparations
FCF
−12.1 M USD
Dette
64.0 k USD
trésorerie nette
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksHRTX principaleUSD0.3582 -6.79%actions ordinaires
LSE London Stock Exchange0J4V IOBUSD0.3653 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Rubric Capital Managemen…15.83%30.05 M2026-06-30
Clearline Capital, LP6%11.38 M2026-06-30
Blackrock Inc.5.56%10.55 M2026-06-30
MORGAN ADAM (Director)≈4.68%8.88 M2026-01-30
Velan Capital Investment…4.61%8.75 M2026-06-30
Vanguard Capital Managem…4.1%7.78 M2026-06-30
Tejara Capital Ltd3.43%6.51 M2026-06-30
Tang Capital Management,…3.29%6.25 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.88%5.47 M2026-06-30
Geode Capital Management…2.25%4.27 M2026-06-30
Millennium Management Ll…2.14%4.07 M2026-06-30
JW Asset Management, LLC1.98%3.75 M2026-06-30
iShares Trust-iShares Ru…1.91%3.63 M2026-08-31
VANGUARD INDEX FUNDS-Van…1.09%2.06 M2026-06-30
Fidelity Salem Street Tr…0.86%1.63 M2026-07-31
iShares Trust-iShares Ru…0.72%1.37 M2026-08-31
SCHWAB STRATEGIC TRUST-S…0.46%869 9042026-05-31
COLLARD CRAIG ALEXANDER…≈0.45%856 4922026-07-31
VANGUARD SCOTTSDALE FUND…0.41%783 9922026-05-31
Fidelity Concord Street…0.33%635 7122026-07-31
iShares Trust-iShares Mi…0.28%533 8002026-08-31
iShares Trust-iShares Ru…0.27%504 9822026-08-31
DUARTE IRA (Chief Financ…≈0.15%281 8992026-07-31
FORBES WILLIAM P (Office…≈0.13%241 1732026-07-31
HENSLEY MARK EARL (Chief…≈0.09%170 9012026-08-06
RODRIGUEZ SUSAN (Directo…≈0.05%87 1802025-01-31
CUSACK THOMAS J (Directo…≈0.03%53 9602026-01-30
JOHNSON CRAIG A (Directo…≈0.03%53 9602026-01-30
KASETA MICHAEL (Director…≈0.03%53 9602026-01-30
RUBRIC CAPITAL MANAGEMEN…——2025-10-15